News

Santé log52m
Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with Prestigious Lifetime Achievement Award by The American Business Awards®
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today ...
Santé log52m
Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2. All three cohorts show separation from placebo ...
Santé log52m
Accumulus Synergy et Veeva Systems s’associent afin d’accélérer la transformation réglementaire et la connectivité
Le partenariat entre Accumulus et Veeva reflète une vision commune d’un écosystème où la collaboration favorise le progrès et où les sponsors disposent de solutions pertinentes. Accumulus et Veeva ...
Santé log52m
Design Therapeutics Announces Start of Friedreich Ataxia Patient Dosing Ex-U.S. in its RESTORE-FA Phase 1/2 Multiple-Ascending Dose Trial of DT-216P2
About DT-216P2 DT-216P2 is an improved formulation of a GeneTAC ® small molecule designed to specifically target the GAA repeat expansion mutation that is the underlying cause of FA and restore the ...
Santé log52m
Apellis Pharmaceuticals to Present at the Goldman Sachs 46th Annual Global Healthcare Conference
WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46 th Annual Global Healthcare ...
Santé log52m
Helius Medical Technologies, Inc. Compliant with Nasdaq Bid Price Rule Listing Criteria
Helius Medical Technologies, Inc. (Nasdaq:HSDT) (“Helius” or the “Company”), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today ...
Santé log52m
Upstream Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
About Upstream Bio Upstream Bio is a clinical-stage biotechnology company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders. The Company is ...
Santé log52m
Sagimet Biosciences Announces Positive Phase 3 Results for Denifanstat for the Treatment of Moderate-to-Severe Acne from Partner Ascletis
Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of moderate to severe acne Sagimet initiated first-in-human Phase 1 clinical trial of a second FASN inhibitor, ...
Santé log52m
Sharps Technology Begins Shipments Across Three Customer Orders Under Previously Announced Purchase Agreements
Sharps Technology, Inc. (Nasdaq: “STSS” and “STSSW”) (“Sharps”), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the ...
Santé log52m
Accumulus Synergy and Veeva Systems Partner to Advance Regulatory Transformation and Connectivity
The Accumulus-Veeva partnership represents a shared vision for an ecosystem where collaboration drives progress and sponsors are empowered with meaningful solutions. Accumulus and Veeva are ...
Santé log52m
Revive Therapeutics Advances with Next-Generation Bucillamine Development
Revive is strategically positioning New Bucillamine to target public health emergencies such as pandemic influenza and emerging infectious diseases. Additionally, the company will pursue FDA ...
Santé log52m
The Joint Corp. Appoints Sandi Karrmann as Director
SCOTTSDALE, Ariz., June 04, 2025 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), the nation's largest provider of chiropractic care through The Joint Chiropractic® network, appointed Sandi ...